RVNC Revance Therapeutics Inc.

-0.3  -2%
Previous Close 17.69
Open 17.68
Price To Book 3.54
Market Cap 643215529
Shares 36,987,667
Volume 118,535
Short Ratio
Av. Daily Volume 495,546

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 completion of enrolment due 2H 2019.
Plantar fasciitis
Phase 3 endpoints not met June 2016
Lateral Canthal (Crow’s Feet) Lines
Phase 3 completion of enrolment due early 2020.
Cervical dystonia
BLA filing due 1H 2019.
Moderate to severe glabellar (frown) lines
Phase 2 trial to be initiated 2019.
Chronic migraine
Phase 2 completion of enrolment due 2H 2019.
Upper limb spasticity

Latest News

  1. Revance to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019
  2. CohBar Announces the Appointment of Dr. Phyllis Gardner to its Board of Directors
  3. Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines
  4. What Kind Of Shareholders Own Revance Therapeutics, Inc. (NASDAQ:RVNC)?
  5. Investor Expectations to Drive Momentum within International Paper, Gray Television, Nielsen Holdings Plc, e.l.f. Beauty, NIC, and Revance Therapeutics — Discovering Underlying Factors of Influence
  6. Revance Announces Closing of Public Offering of Common Stock
  7. Revance Announces Pricing of Public Offering of Common Stock
  8. The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen
  9. Revance Announces Proposed Public Offering of Common Stock
  10. Revance Announces Ground-Breaking Data Presentations at Leading International Neurotoxin Conference
  11. Revance Highlights Recent Regulatory Progress and Provides Anticipated 2019 Milestones
  12. Today's Research Reports on Trending Tickers: Novelion Therapeutics and Revance Therapeutics
  13. Revance Therapeutics reaches licensing agreement with Fosun Pharmaceutical over botox formulation RT002
  14. Revance Therapeutics' Botox rival succeeds in late-stage trial
  15. Revance Announces China Market License Agreement with Fosun Pharma for RT002
  16. Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program
  17. Market Trends Toward New Normal in Palatin Technologies, Revance Therapeutics, Geo Group, QUANTENNA COMMS, The Navigators Group, and INVESCO MORTGAGE CAPITAL INC — Emerging Consolidated Expectations, Analyst Ratings
  18. Revance to Participate in Upcoming Investor Conferences
  19. Edited Transcript of RVNC earnings conference call or presentation 1-Nov-18 8:30pm GMT
  20. Why Revance Therapeutics Inc’s (NASDAQ:RVNC) CEO Pay Matters To You